- Home
- TRT vs QTTB Comparison
TRT vs QTTB Comparison
Compare TRT & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRT | QTTB |
|---|---|---|
| Founded | 1958 | 2015 |
| Country | United States | United States |
| Employees | N/A | 22 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.0M | 450.1M |
| IPO Year | 1995 | 2018 |
Fundamental Metrics
Financial Performance| Metric | TRT | QTTB |
|---|---|---|
| Price | $9.23 | $15.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 422.9K | ★ 2.0M |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 136.78 |
| EPS | ★ 0.02 | N/A |
| Revenue | $32,462,000.00 | ★ $53,737,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $495.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.42 | $1.57 |
| 52 Week High | $21.38 | $23.57 |
Technical Indicators
Market Signals| Indicator | TRT | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 40.89 | 53.98 |
| Support Level | $6.47 | $4.04 |
| Resistance Level | $9.50 | $23.57 |
| Average True Range (ATR) | 1.02 | 2.03 |
| MACD | -0.06 | -0.16 |
| Stochastic Oscillator | 0.00 | 34.14 |
Price Performance
Historical ComparisonAbout TRT Trio-Tech International
Trio-Tech International is a provider of reliability test equipment and services to the semiconductor and other industries. Its customers are from automotive electronics, industrial electronics, computing and data storage, consumer electronics, and communication markets. The company operated its business in two segments: Semiconductor Back-end Solutions and Industrial Electronics. Geographically, the company operates in the United States (U.S), Singapore, Malaysia, Thailand and China.
About QTTB Q32 Bio Inc.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).